Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) CEO Gerald Commissiong tells Proactive Investors the company's central nervous system asset is moving to Phase 2b clinical trials later this year.
Commissiong also says the company is moving its headquarters to New York from San Francisco to raise more capital.
Meet360 Blockchain Inc at our event,New York, 18 April 2018.Register here >>